» Articles » PMID: 38989058

Mechanistic Insights into P-glycoprotein Ligand Transport and Inhibition Revealed by Enhanced Molecular Dynamics Simulations

Overview
Specialty Biotechnology
Date 2024 Jul 11
PMID 38989058
Authors
Affiliations
Soon will be listed here.
Abstract

P-glycoprotein (P-gp) plays a crucial role in cellular detoxification and drug efflux processes, transitioning between inward-facing (IF) open, occluded, and outward-facing (OF) states to facilitate substrate transport. Its role is critical in cancer therapy, where P-gp contributes to the multidrug resistance phenotype. In our study, classical and enhanced molecular dynamics (MD) simulations were conducted to dissect the structural and functional features of the P-gp conformational states. Our advanced MD simulations, including kinetically excited targeted MD (ketMD) and adiabatic biasing MD (ABMD), provided deeper insights into state transition and translocation mechanisms. Our findings suggest that the unkinking of TM4 and TM10 helices is a prerequisite for correctly achieving the outward conformation. Simulations of the IF-occluded conformations, characterized by kinked TM4 and TM10 helices, consistently demonstrated altered communication between the transmembrane domains (TMDs) and nucleotide binding domain 2 (NBD2), suggesting the implication of this interface in inhibiting P-gp's efflux function. A particular emphasis was placed on the unstructured linker segment connecting the NBD1 to TMD2 and its role in the transporter's dynamics. With the linker present, we specifically noticed a potential entrance of cholesterol (CHOL) through the TM4-TM6 portal, shedding light on crucial residues involved in accommodating CHOL. We therefore suggest that this entry mechanism could be employed for some P-gp substrates or inhibitors. Our results provide critical data for understanding P-gp functioning and developing new P-gp inhibitors for establishing more effective strategies against multidrug resistance.

Citing Articles

ATP-Binding Cassette and Solute Carrier Transporters: Understanding Their Mechanisms and Drug Modulation Through Structural and Modeling Approaches.

Elbahnsi A, Dudas B, Callebaut I, Hinzpeter A, Miteva M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770445 PMC: 11676857. DOI: 10.3390/ph17121602.

References
1.
Fox E, Bates S . Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 2007; 7(4):447-59. DOI: 10.1586/14737140.7.4.447. View

2.
Aller S, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R . Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009; 323(5922):1718-22. PMC: 2720052. DOI: 10.1126/science.1168750. View

3.
Kabsch W, Sander C . Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983; 22(12):2577-637. DOI: 10.1002/bip.360221211. View

4.
Lomize M, Pogozheva I, Joo H, Mosberg H, Lomize A . OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 2011; 40(Database issue):D370-6. PMC: 3245162. DOI: 10.1093/nar/gkr703. View

5.
Siarheyeva A, Liu R, Sharom F . Characterization of an asymmetric occluded state of P-glycoprotein with two bound nucleotides: implications for catalysis. J Biol Chem. 2010; 285(10):7575-86. PMC: 2844205. DOI: 10.1074/jbc.M109.047290. View